Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...